|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-10-30
|
|
pubmed:abstractText |
New strategies for control of leishmaniasis is needed as chemotherapy using antimonial drugs is prolonged, expensive, associated with side effects and relapses. Vector control has limitations and a vaccine which may be the best approach is not available.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0012-835X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
84-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11682952-Animals,
pubmed-meshheading:11682952-Antibodies, Protozoan,
pubmed-meshheading:11682952-Disease Models, Animal,
pubmed-meshheading:11682952-Drug Evaluation, Preclinical,
pubmed-meshheading:11682952-Glycosphingolipids,
pubmed-meshheading:11682952-Insect Vectors,
pubmed-meshheading:11682952-Leishmania major,
pubmed-meshheading:11682952-Leishmaniasis, Cutaneous,
pubmed-meshheading:11682952-Metalloendopeptidases,
pubmed-meshheading:11682952-Mice,
pubmed-meshheading:11682952-Mice, Inbred BALB C,
pubmed-meshheading:11682952-Phlebotomus,
pubmed-meshheading:11682952-Protozoan Vaccines
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.
|
|
pubmed:affiliation |
Centre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O. Box 54840, Nairobi, Kenya.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
